Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arrow International’s Carl Anderson

This article was originally published in The Gray Sheet

Executive Summary

Newly appointed chairman and CEO will succeed Marlin Miller Sept. 1. Anderson currently is vice chairman of Arrow and general manager of the firm's critical care business. The exec has been a director since 1998 and has served with ABC School Supply, Inc., James River Corp. and Procter & Gamble. Miller, who has been with Arrow since 1975, will continue as a director and chairman emeritus. Arrow expects a CE mark for its LionHeart left-ventricular assist device within weeks...

You may also be interested in...

American Heart Association 2003 Scientific Sessions In Brief

Arrow takes aim at Thoratec data: Adverse event rate associated with Arrow International's LionHeart left-ventricular assist device in the European Clinical Utility Baseline Study (CUBS) is comparable to Thoratec's HeartMate VE in the REMATCH trial, Arrow contends. Results of the destination LVAD therapy trial were presented by John Boehmer, MD, Pennsylvania State University, at the American Heart Association annual scientific sessions in Orlando Nov. 10. In CUBS, LionHeart was associated with 7.56 adverse events per patient-year, compared with 6.39 in REMATCH. Boehmer notes, however, that CUBS represents LionHeart's first clinical experience, while HeartMate had been implanted in 1,000 patients as a bridge to transplant prior to REMATCH (1"The Gray Sheet" June 30, 2003, In Brief)...

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts